Shots:

• The first patient has been dosed in a P-III clinical study evaluating the efficacy and safety of BAT2206 vs reference Stelara in ~ 472 patients with moderately to severely PsO
• BAT2206 represents the 4th biosimilar of Bio-Thera's portfolio to enter P-III study. The advancement of BAT2206 in P-III study demonstrates company’s commitment to develop biosimilars to expand patient access at lower costs
• Bio-Thera Solutions is developing additional proposed biosimilars- including a bevacizumab biosimilar and a tocilizumab biosimilar that have completed global P- III clinical trials. The company is also pursuing biosimilar versions of golimumab- mepolizumab- and dupilumab

  Ref: Businesswire | Image: Businesswire